This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schmieder, R. E. Articles by Nunez, B. D. Search for Related Content PubMed PubMed Citation Articles by Schmieder, R. E. Articles by Nunez, B. D.

Circulation, Vol 75, 1030-1036, Copyright © 1987 by American Heart Association

ARTICLES

Cardiovascular effects of verapamil in patients with essential hypertension

RE Schmieder, FH Messerli, GE Garavaglia and BD Nunez

The cardiovascular effects of intravenous verapamil and 3 months of oral administration of a slow-release form of verapamil (verapamil-SR) were studied in 10 patients with mild-to-moderate essential hypertension. Intravenous verapamil reduced arterial pressure by 15% (p less than .01) through a fall in total peripheral resistance of 29% (p less than .01); provoked a reflexive rise in heart rate (by 19%, p less than .02), cardiac output (by 74%, p less than .01), and plasma catecholamines; and shifted intravascular volume toward the cardiopulmonary circulation indicating peripheral venoconstriction. Quite in contrast to the immediate effects of the intravenous drug, oral therapy with verapamil-SR for 2 to 3 months lowered arterial pressure effectively (by 15%, p less than .01) by inducing vasodilation of 15% (p less than .02), but without causing reflex tachycardia, activation of the sympathetic-adrenergic or renin-angiotensin systems, or volume expansion. Oral therapy with verapamil-SR preserved systemic and renal blood flow and slightly reduced cardiac mass (by 6%, p less than .05) and renal vascular resistance (by 25%, p less than .05). Whereas intravenous verapamil tended to depress myocardial contractility, oral verapamil-SR did not at all affect myocardial contractility or left ventricular function. These cardiovascular effects make verapamil-SR an excellent agent for long-term antihypertensive therapy.

This article has been cited by other articles:

				S. Dhar, D. Koul, and G. E. D'Alonzo Jr Current Concepts in Diastolic Heart Failure J Am Osteopath Assoc, April 1, 2008; 108(4): 203 - 209. [Abstract] [Full Text] [PDF]

				E. Schroder, J. Magyar, D. Burgess, D. Andres, and J. Satin Chronic verapamil treatment remodels ICa,L in mouse ventricle Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1906 - H1916. [Abstract] [Full Text] [PDF]

				M. Kingsbury, A. Mahnke, M. Turner, and D. Sheridan Recovery of coronary function and morphology during regression of left ventricular hypertrophy Cardiovasc Res, July 1, 2002; 55(1): 83 - 96. [Abstract] [Full Text] [PDF]

				M. T. Kailasam, R. J. Parmer, J. H. Cervenka, R. A. Wu, M. G. Ziegler, B. P. Kennedy, I. A. Adegbile, and D. T. O'Connor Divergent Effects of Dihydropyridine and Phenylalkylamine Calcium Channel Antagonist Classes on Autonomic Function in Human Hypertension Hypertension, July 1, 1995; 26(1): 143 - 149. [Abstract] [Full Text]